CTO (Chronic total occlusion)

Find all the latest content on chronic total occlusion (CTO) published on this website.

Recently we have seen an increase in successful percutaneous coronary interventions (PCI) of CTO in part due to improvements in hardware (guidewires and balloons), the introduction of dedicated devices (microcatheters, channel dilators, dissection-reentry devices) and the elaboration of CTO-specific techniques. To fully grasp CTO today, here you will find here everything that you need to know including the latest devices and techniques as well as advances in imaging, the use of adjunctive pharmacotherapy, vascular access or understanding bleeding risks…

Filtered By

187 results

2017 ESC Focused update on Dual Antiplatelet Therapy (DAPT)

04 Sep 2017

As dual antiplatelet therapy (DAPT) seems to have been interventionalists’ close companion since the pioneering studies showing its benefits over oral anticoagulants (OAC) some 20 years ago, the myriad of ensuing studies has led to expanding indications, but has also uncovered the inherent risks of DAPT. In the 2017 Focused Update, the hitherto accumulated evidence is eloquently summarized into a set of recommendations that provide guidance on some of the important questions of an interventional cardiologist's everyday practice: which of the currently available P2Y12 inhibitors should be selected, what is the optimal duration of DAPT and how to manage bleeding complications.

Dejan Milasinovic


Dejan Milasinovic

Ticagrelor or clopidogrel in DAPT for acute coronary syndromes: A call for a stepwise approach?

Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study

28 Aug 2017

Christopher Cook


Christopher Cook

Better stents, IVUS, FFR, medical therapy…or the integration of all? The SYNTAX-II trial

27 Aug 2017

EuroCTO: What is the best option for treating CTO: PCI or optimal medical therapy?

From EUROPCR 2017

Which approach best improves clinical symptoms? Join G. Werner as he reviews this randomized trial whose goal was the assessment of these two strategies and their impact on the overall health of patients at 12 months. Learn of the specificities of this trial including how patients with multivessel disease were included in both arms, as well as the efficacy of either treatment or the number of crossovers after intention-to-treat was decided upon. Finally, which approach proved to be more successful in improving angina frequency or quality of life? Learn more here.

EuroPCR 2017: EuroCTO trial: better quality of life for patients with CTO PCI compared with OMT

CTO, innovative approaches

19 May 2017 – From EuroPCR 2017

Frequent treatment dilemmas in coronary interventions

19 May 2017 – From EuroPCR 2017

EuroPCR 2017: Fresh data on OCT management, FFR guidance and bioresorbable stents

Participants saw exciting results from a number of late-breaking trials during EuroPCR 2017, focusing on such topics as chronic total occlusions (CTO), neurological outcomes following TAVI in intermediate-risk patients, and bioresorbable vs. bare metal stents.

Serbia and Siberia share their most educational cases: CTO PCI: teaching points from challenging cases in everyday practice

18 May 2017 – From EuroPCR 2017